An updated meta-analysis of available CVOTs, published 2 years later, also confirmed that GLP-1 receptor agonists decrease the risk for fatal or non-fatal AMI by 10% in patients with type 2 DM, compared to placebo, demonstrating a significant treatment benefit for patients with type 2 DM being at high cardiovascular risk or having a history of ASCVD [51]. This evidence concerns the gene GLP1R and atherosclerosis.